Labcorp(LH) - 2025 Q4 - Annual Report

Revenue Growth - The Company's revenues for the year ended December 31, 2025, were $13,951.7 million, a 7.2% increase from $13,008.9 million in 2024, driven by organic revenue growth of 4.4%, acquisitions net of divestitures contributing 2.5%, and favorable foreign currency translation of 0.4%[217] - Dx segment revenues increased to $10,876.5 million, up 7.2% from $10,144.3 million in 2024, with organic revenue growth of 4.1% and acquisitions net of divestitures contributing 3.2%[221] - BLS segment revenues reached $3,098.2 million, a 6.0% increase from $2,922.6 million in 2024, primarily due to organic growth of 4.0% and favorable foreign currency translation of 2.0%[223] Cost and Expenses - Cost of revenues increased by 5.9% to $9,939.2 million, while the cost of revenues as a percentage of revenues decreased to 71.2% from 72.1% in 2024, reflecting operational efficiencies[224] - Selling, general, and administrative expenses were $2,230.0 million, a slight increase of 0.6% from $2,216.3 million in 2024, with the percentage of revenues decreasing to 15.9% from 17.1%[225] - The Company recorded net restructuring charges of $127.2 million for 2025, a significant increase of 176.5% from $46.0 million in 2024, primarily due to restructuring activities[228] Interest and Taxes - Interest expense rose by 7.6% to $224.1 million in 2025, compared to $208.3 million in 2024, driven by higher weighted-average interest rates[230] - The provision for income taxes was $229.8 million, with an effective tax rate decreasing to 20.7% from 22.1% in 2024, mainly due to the release of specific uncertain tax positions[233] Cash Flow and Liquidity - The Company's net cash provided by operating activities was $1,640.5 million, an increase from $1,585.8 million in 2024, attributed to higher cash earnings[240] - Cash and cash equivalents at December 31, 2025, totaled $532.3 million, down from $1,518.7 million in 2024, indicating a decrease in liquidity[239] - Net cash used for financing activities in 2025 was $1,457.0 million, a decrease from net cash provided of $779.9 million in 2024, primarily due to a $2,000.0 million decrease in proceeds from senior note offerings[244] Capital Expenditures and Financing - Capital expenditures for the year ended December 31, 2025, were $434.5 million, representing 3.1% of revenues, with an expected increase to 4.0% in 2026[243] - The company had $1,000.0 million of available borrowings under its revolving credit facility, which was amended on June 27, 2025, and expires in 2030[245] - The company borrowed an additional $225.0 million under its accounts receivable facility, bringing the total outstanding to $525.0 million as of December 31, 2025[246] Future Obligations - As of December 31, 2025, the company had total future payments of $5,622.6 million, with $500.3 million payable within 12 months[254] - The company expects to pay up to $415.0 million in connection with pending acquisitions, including $85.0 million contingent on performance[256] - The company had total future lease payments of $1,144.3 million, with $234.4 million due within 12 months[255] Compliance and Ratings - The company is in compliance with all covenants under its credit facilities and expects to remain compliant for the next 12 months[245] - The company has investment grade credit ratings from Moody's and S&P Global Ratings, enhancing its ability to access capital markets[252] Accounting and Impairment - The Company accounts for business combinations using the acquisition method, recording acquired assets at estimated fair values as of the acquisition date[273] - The Company recognizes deferred tax assets and liabilities based on differences between financial statement carrying amounts and tax bases, measured using enacted tax rates[274] - The Company performed its annual goodwill impairment testing as of October 1, 2025, concluding that the fair values of each reporting unit exceeded their carrying values[281] - The Company assesses goodwill and indefinite-lived intangible assets for impairment at least annually or when circumstances indicate potential impairment[276] Foreign Exchange Exposure - Approximately 13.5% of the Company's revenues for the year ended December 31, 2025, were denominated in currencies other than USD, with significant exposure to CAD, Swiss Franc, Euro, and British Pound[289] - A hypothetical 10% change in average exchange rates would have impacted income before income taxes for 2025 by approximately $31.7 million[289] - The Company had eight open foreign exchange forward contracts with a notional value totaling approximately $238.0 million as of December 31, 2025[290] - The Company is a party to cross-currency swap agreements with an aggregate notional amount of $1,200.0 million to hedge against foreign exchange movements[291] - The Company entered into fixed-to-variable interest rate swap agreements for $500.0 million of senior notes due 2031 to hedge against changes in fair value[294] Legal Reserves - The Company records an aggregate legal reserve based on historical loss rates and trends in settlements and defense costs[287]